Expression of Ku86 and presence of Ku86 Antibody as biomarkers of hepatitis B virus related hepatocellular carcinoma

Digestive Diseases and Sciences

Volumn 59, Issue 3, 2014, Pages 614-622

  Xu, Yong ^a   Liu, Ai Jun ^b   Gao, Yuan Xing ^c   Hu, Ming Gen ^a   Zhao, Guo Dong ^a   Zhao, Zhi Ming ^a   Liu, Rong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Shangluo Central Hospital   (China)

^c First Hospital of Qiqihaer   (China)

Author keywords

Hepatocellular carcinoma; Ku86; Ku86 antibody; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; ANTIBODY; KU86 ANTIBODY; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL DIFFERENTIATION; CHILD PUGH SCORE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HEPATITIS B VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SURVIVAL TIME; TUMOR DIFFERENTIATION; TUMOR VOLUME; YOUDEN INDEX;

AGED; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DNA HELICASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; ROC CURVE; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896724773     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-013-2941-1     Document Type: Article

References (20)

1. Tinkle CL, Haas-Kogan D. Hepatocellular carcinoma: Natural history, current management, and emerging tools. Biologics. 2012;6:207-219.
2. Chen Y, Zhang H, Liao W, et al. FOXP3 gene polymorphism is associated with hepatitis B-related hepatocellular carcinoma in China. J Exp Clin Cancer Res. 2013;32:39.
3. Takayasu K, Muramatsu Y, Mizuguchi Y, et al. Imaging of early hepatocellular carcinoma and adenomatous hyperplasia (dysplastic nodules) with dynamic ct and a combination of CT and angiography: Experience with resected liver specimens. Intervirology. 2004;47:199-208.
4. Frericks BB, Loddenkemper C, Huppertz A, et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol. 2009;193:1053-1060.
5. Nomura F, Ohnishi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1989;64: 1700-1707.
6. Hayashi J, Sakata KI, Someya M, et al. Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett. 2012;4:151-155.
7. Someya M, Sakata KI, Matsumoto Y, et al. The association of DNA-dependent protein kinase activity of peripheral blood lymphocytes with prognosis of cancer. Br J Cancer. 2011;104: 1724-1729.
8. Kongruttanachok N, Phuangphairoj C, Thongnak A, et al. Replication independent DNA double-strand break retention may prevent genomic instability. Mol Cancer. 2010;9:70.
9. Tong WM, Cortes U, Hande MP, et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 2002;62: 6990-6996.
10. Lim JW, Kim H, Kim KH. Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells. J Biol Chem. 2002;277: 46093-46100.
11. Nomura F, Sogawa K, Noda K, et al. Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun. 2012;421:837-843.
12. Wu F, Wu L, Zheng S, et al. The clinical value of hepatocyte growth factor and its receptor-c-met for liver cancer patients with hepatectomy. Dig Liver Dis. 2006;38:490-497.
13. Yang L, Rong W, Xiao T, et al. Secretory/releasing proteomebased identification of plasma biomarkers in HBV-associated hepatocellular carcinoma. Sci China Life Sci. 2013;56:638-646.
14. Tameda M, Shiraki K, Sugimoto K, et al. Des-gamma-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma. Cancer Sci. 2013;104:725-731.
15. Paul D, Biswas R, Habib SH. Tissue polypeptide specific antigen as a marker used to determine the liver diseases. Kathmandu Univ Med J (KUMJ). 2011;9:24-27.
16. Moeller BJ, Yordy JS, Williams MD, et al. DNA repair biomarker profiling of head and neck cancer: Ku80 expression predicts locoregional failure and death following radiotherapy. Clin Cancer Res. 2011;17:2035-2043.
17. Lagadec C, Romon R, Tastet C, et al. Ku86 is important for TrkA overexpression-induced breast cancer cell invasion. Proteomics Clin Appl. 2010;4:580-590.
18. Suzuki H, Graziano DF, McKolanis J, et al. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin Cancer Res. 2005;11:1521-1526.
19. Piura E, Piura B. Autoantibodies to tumor-associated antigens in breast carcinoma. J Oncol. 2011;2011:982425.
20. Caramori G, Adcock IM, Casolari P, et al. Unbalanced oxidantinduced DNA damage and repair in COPD: A link towards lung cancer. Thorax. 2011;66:521-527.